Effector proteins of Rapamycin
AssigneeWyeth
InventorsThomas J. Caggiano, Yanqiu Chen, Amedeo A. Failli, Katherine L. Molnar-Kimber, Koji Nakanishi
Life of this patent
Estimating the term…
Abstract
This invention comprises novel Rapamycin-FKBP12 binding proteins of mammalian origin for identification, design and synthesis of immunomodulatory, anti-restenosis or anti-tumor agents, as well as fragments of the proteins and the DNA, cDNA, antisense RNA and DNA segments corresponding to the proteins. This invention also comprises methods for isolating the proteins and therapeutic uses related to the proteins.
Claims3
An isolated protein having a molecular weight of about 210 kDa as determined by SDS-PAGE or fragment thereof, the protein made by a process comprising the steps of:
- (a) providing a sample of human cellular material;
- (b) preparing an extract of the cellular material comprising cell membrane proteins;
- (c) contacting the extract with an affinity reagent comprising a complex of:
- (i) rapamycin and
- (ii) FKBP12 under conditions which permit materials capable of specifically binding to the affinity reagent to bind thereto;
- (d) separating materials which do not bind to the affinity reagent from the affinity reagent and the materials bound thereto;
- (e) dissociating the materials bound to the affinity reagent therefrom;
- and
- (f) separating the protein having a molecular weight of about 210 kDa or fragment thereof from the other materials dissociated from the affinity reagent, wherein the 210 KDa protein or fragment thereof specifically binds to the rapamycin-FKBP12 complex.
An isolated protein having a molecular weight of about 210 kDa, as determined by SDS-PAGE, or a fragment thereof, wherein said protein is a rapamycin effector protein which can be obtained from a human, and wherein said protein or fragment binds to a complex comprising:
- a) FKBP12 and
- b) rapamycin.
Dependencies are inferred from the claim text.